Bundibugyo Ebola explained: the rare virus behind Congo's outbreak, and why no vaccine is approved for it

The Health Ministry of the Democratic Republic of the Congo, referred to here as Congo, reported on October 1, 2026, that 4,018 people have died among 8,300 cases recorded since the outbreak was declared in eastern Congo on May 15. Five days later the virus surfaced in another country. Kenya confirmed that a citizen who had flown in from Congo via Uganda tested positive and died in a Nairobi hospital, and Kenya is the fourth country to record an Ebola case in the current outbreak.

The Associated Press describes it as the fastest-growing Ebola outbreak in history. It is also unusual in its cause. The outbreak is caused by the rare Bundibugyo virus, for which there is no approved vaccine or treatment.

This explainer sets out what that virus is, how it differs from the Ebola virus most people have heard of, and what is and is not known about it.

What Bundibugyo Ebola virus is

“Ebola” is a family name. The World Health Organization counts six related viruses in the group, and three different viruses are known to cause large Ebola disease outbreaks: Ebola virus, Sudan virus and Bundibugyo virus. The first of those, once called Zaire ebolavirus, caused the West African epidemic of 2014 to 2016. It is the one that vaccines and drugs were built for.

Bundibugyo virus is the newest of the three. The first known Ebola hemorrhagic fever (EHF) outbreak caused by Bundibugyo Ebola virus occurred in Bundibugyo District, Uganda, in 2007. The district lies in the west of the country, on the border with Congo.

Its discovery began with a failed test. Samples from sick patients were sent to the Centers for Disease Control and Prevention in Atlanta, where the most sensitive genetic tests for Ebola came back negative even though a broader antibody test was positive. Sequencing explained why: the sequence was distinct from the four known species of ebolavirus. The CDC team measured the gap at approximately 32% nucleotide difference from even the closest relative, meaning about a third of the genetic letters differed. That first outbreak resulted in 149 suspected cases and 37 deaths. Those totals include suspected cases that were never confirmed, which is why they give a lower death rate than the laboratory-confirmed group described below.

In its 2026 research priorities the WHO still calls it one of the least studied members of the group. Bundibugyo virus remains one of the least studied Orthoebolaviruses with no licensed vaccine or treatment, the agency wrote in September.

How Bundibugyo Ebola spreads and what it does

Ebola viruses live in animals between human outbreaks. It is thought that fruit bats of the Pteropodidae family are natural hosts, the WHO says, and people are first infected through contact with infected wildlife.

From there it passes between people by touch. Infection requires direct contact with the blood or body fluids of someone who is sick or has died, or with objects those fluids have contaminated. Three facts shape how outbreaks unfold. People cannot transmit the disease before they have symptoms, and they remain infectious as long as their blood contains the virus. And the dead are infectious too, so that burial ceremonies that involve direct contact with the body of a person who has died can also contribute to the transmission. Health workers are at particular risk, and in Congo at least 50 health workers have died after contracting the virus.

The illness starts like many others. The incubation period or interval from infection to onset of symptoms varies from 2 to 21 days. Fever, fatigue, muscle pain, headache and sore throat come first, followed by vomiting, diarrhea and abdominal pain, and then signs that the kidneys and liver are failing.

The image of Ebola as a bleeding disease is partly wrong. Despite a perception that bleeding is a common symptom, this is less frequent and can occur later in the disease, the WHO notes.

The 2007 Uganda patients showed a similar early picture, with more bleeding than that summary would suggest. A CDC-led report on the outbreak’s laboratory-confirmed cases calculated an average incubation period of 6.3 days among laboratory-confirmed patients whose exposure could be dated. Common symptoms were fever, fatigue, headache, nausea or vomiting, abdominal pain, muscle and joint pain, and diarrhea. Bleeding of any type was reported among 54% of all patients with laboratory-confirmed cases.

Because those symptoms resemble malaria and typhoid, the report’s authors concluded that their nonspecific nature made diagnosis based on clinical characteristics alone particularly challenging, and that laboratory confirmation is essential.

How deadly Bundibugyo Ebola is

For Ebola diseases as a whole, the WHO gives a broad range. The average Ebola disease case fatality rate is around 50%, and rates have ranged from 25% to 90% in past outbreaks. Case fatality rate is the share of people with a disease who die of it.

The only detailed figure for Bundibugyo virus comes from Uganda. Researchers there confirmed 56 cases by laboratory test. To calculate the death rate they set aside patients who were identified only after recovery, since those were survivors by definition. Of the 43 cases confirmed from acute-phase samples, 17 deaths occurred, for a proportion of 40%. Those who died were older on average, 42 years against 33 for survivors.

That was lower than the 50% to 90% recorded for the Ebola and Sudan viruses up to that time. The authors did not take the difference at face value. They wrote that it might be an artifact of differences in the severity of laboratory-confirmed cases detected through outbreak surveillance or the quality of care received by patients in hospital. Milder cases that are found and tested pull a death rate down, and good nursing does the same.

The current outbreak’s raw numbers, 4,018 deaths among 8,300 cases, work out to about 48%. That is a crude ratio. It includes patients who are still ill and misses people who were never counted, so it cannot be read as the virus’s true death rate.

Why existing Ebola vaccines and drugs are not approved for Bundibugyo virus

The tools that changed Ebola outbreaks over the past decade were designed against one virus.

The vaccine came out of the West African epidemic. In a trial in Guinea, researchers vaccinated the contacts of each new patient, and the contacts of those contacts, either immediately or after a delay of 21 days, a strategy called ring vaccination. No cases of Ebola virus disease occurred 10 days or more after assignment among those vaccinated at once, versus 16 cases (7 clusters affected) among all eligible individuals in delayed clusters. Vaccine efficacy was calculated at 100%, with a plausible range from 68.9% to 100%.

Treatment followed in Congo. A trial run during the 2018 to 2019 outbreak there compared four drugs, and a total of 681 patients were enrolled. Two antibody treatments proved better than the others. Death within 28 days occurred in 35.1% and 33.5% of patients given those two, against about half of patients given the comparison drug. Antibody treatments of this kind are laboratory-made versions of the proteins the immune system uses to lock onto a virus.

Both the vaccine and the antibodies were developed against the Ebola virus species. When Bundibugyo virus was discovered, the CDC team predicted that its genetic distance would show up in how the immune system recognizes it. They noted that current human prototype ebolavirus vaccines include Zaire and Sudan ebolaviruses, and that the new virus’s genetic distance would matter for vaccine design.

The WHO’s position today reflects that. While there are licensed vaccines and therapeutics for Ebola virus disease, for the other Ebola diseases there are no approved therapeutics, but candidate products are under development. On its page for this outbreak the agency says the Bundibugyo species of Ebola involved is one for which there is no vaccine or specific treatment, though work is ongoing to test promising candidates. It issued emergency guidance on September 1 on the potential use of the licensed vaccine, Ervebo, in Bundibugyo outbreaks. Vaccine and treatment trials are underway in Congo’s Ituri province, the AP reported.

The Congo drug trial left one lesson that applies to any Ebola virus. Its authors wrote that scientifically and ethically sound clinical research can be conducted during disease outbreaks.

How a Bundibugyo Ebola outbreak is brought under control

Without a proven vaccine, control depends on older methods: finding cases quickly, isolating them, tracing and monitoring everyone they touched, burying the dead safely and protecting health workers. Kenya’s response to its single case shows the routine. Twenty-eight contacts were identified, and the contacts will remain in isolation for 21 days, the longest incubation period.

Care itself saves lives even without a specific drug. Early intensive supportive care with rehydration and the treatment of symptoms improves survival, the WHO says.

Speed of diagnosis matters as well. In Butembo, test results that used to take 72 hours can now be obtained in six hours with the mobile labs, a doctor at a treatment center told the AP.

All of that requires cooperation and security, and eastern Congo has little of either. The WHO describes a humanitarian crisis in a remote and densely populated area, with insecurity and heavy cross-border movement. An Ebola transit center in a displacement camp was burned by soldiers in late September. “When we lose a center, that means we lose capacity, we lose investment, and we have to start again,” said Julien Harneis, the United Nations senior Ebola coordinator.

The WHO’s own summary of the task is blunt: it is only when communities are engaged in the response that such outbreaks are brought under control.

There are signs of slowing, with caveats. Weekly counts fell from around 850 cases and 470 deaths a week in mid-July to an average of 490 cases and 230 deaths a week in September. Africa’s public health agency cautioned that part of the fall may reflect insecurity and poor access in some of the worst-hit areas. Even so, the WHO has said the current outbreak is on track to exceed the deadliest on record, West Africa’s regional outbreak between 2014 and 2016, which killed 11,000 people.

So far spread beyond Congo has been limited. Uganda recorded 20 cases and France one, and Uganda declared its outbreak over in late August.

What is still unknown about Bundibugyo Ebola

Clinical knowledge of this virus rests on a narrow base. The 40% death rate comes from 43 patients in one outbreak, recorded on case forms filled in at triage, and its authors said those forms may not capture the full course of illness.

Whether the licensed vaccine or antibody drugs give any protection against Bundibugyo virus in people has not been established, and the WHO describes the vaccine’s use in this outbreak as potential. The trials now running in Ituri have not reported results.

The outbreak figures are provisional. They come from a health ministry working amid strikes by unpaid staff and attacks on facilities, and both cases and deaths may be undercounted.

Bundibugyo virus has gone from 56 confirmed patients in 2007 to more than 8,000 cases this year, and what is known about how deadly it is still rests on that earlier, far smaller outbreak, with no vaccine yet shown to work against it.